Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Longitudinal Study on dry AMD Progression to neo-vascular AMD over a 15-Year Follow-Up Period
Author Affiliations & Notes
  • Sharat Chandra Vupparaboina
    School of Computing, Wichita State University, Wichita, Kansas, United States
  • Elham Sadeghi
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Sandeep Chandra Bollepalli
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Kiran Kumar Vupparaboina
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Jay Chhablani
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Jose Alain Sahel
    Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Sharat Chandra Vupparaboina None; Elham Sadeghi None; Sandeep Chandra Bollepalli None; Kiran Vupparaboina None; Jay Chhablani None; Jose Sahel Avista Therapeutics, Tenpoint, Code C (Consultant/Contractor), Gensight, SparingVision, Meira, Code F (Financial Support), Gensight, Sparing Vision, Avista, Tenpoint, Prophesee, Chronolife, Tilak Healthcare, SharpEye, Cilensee, Vegavect, Code O (Owner), Allotopic Expression, Rod-derived Cone Viability Factor and related patents, Code P (Patent), Patent Royalties, Gensight, Code R (Recipient), Observer : Gensight, SparingVision, Avista, Vegavect. President : Fondation Voir et Entendre, Paris ; President : StreetLab, Paris., Code S (non-remunerative)
  • Footnotes
    Support  The work was supported by the NIH CORE Grant P30 EY08098 to the Dept. of Ophthalmology, the Eye and Ear Foundation of Pittsburgh; the Shear Family Foundation Grant to the University of Pittsburgh Department of Ophthalmology; and an unrestricted grant from Research to Prevent Blindness, New York, NY.
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5697. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sharat Chandra Vupparaboina, Elham Sadeghi, Sandeep Chandra Bollepalli, Kiran Kumar Vupparaboina, Jay Chhablani, Jose Alain Sahel; Longitudinal Study on dry AMD Progression to neo-vascular AMD over a 15-Year Follow-Up Period. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5697.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aims to investigate the progression of dry age related macular degeneration (AMD) afflicted eyes into neo-vascular AMD and discern the influencing factors

Methods : Retrospective data were extracted from electronic health records (EHR) at the University of Pittsburgh Medical Campus (UPMC). The date of initial diagnosis of dry AMD in the eye marked as the index year for the analysis. The year of clinical diagnosis of wet AMD is considered as the conversion year. The study spanned from October 5, 2006, to July 30, 2023. The exclusion criteria comprised monocular patients at their initial visit. Among the 123 eligible eyes, 104 presented with dry AMD at the baseline. Factors like age, gender, smoking habits, no of injections, systemic diseases and past ocular diseases like glaucoma were studied to assess their influence over progression

Results : The eyes were split into four groups based on the time it took to develop wet AMD: Group 1 within 5 years, Group 2 between 5-10 years, Group 3 between 10-15 years, and Group 4 not converting by the study's conclusion (Figure 1). Out of 104 dry AMD eyes, 49 converted to wet AMD, the average time taken to develop wet AMD was 7.4 years. The average age at presentation was 71.16 for converted eyes and 66.75 for non-converted, a statistically significant difference (t-Test, p-value: 0.017). Survival analysis indicated a 52.88% survival probability for dry AMD eyes by the study's conclusion. A mixed linear model regression showed smokers had worse visual acuity (VA) (+0.21 logMAR) than non-smokers (p-value: 0.019). Female smokers had more significant visual acuity decline than male smokers (Figure 2). Visual acuity worsened more for the converted group (from 0.15 to 0.87, 6 times worse) than the non-converted group (from 0.14 to 0.43, 3 times worse). A chi-square test between smokers and non-smokers and conversion to wet AMD did not show any statistical significance

Conclusions : Our analysis revealed that female smokers experienced a more noticeable decline in visual acuity compared to male smokers over time. While smoking didn't affect the likelihood of developing wet AMD, smokers, in general, had markedly poorer visual acuity than non-smokers. Additionally, baseline systemic conditions such as hypertension, diabetes, and the number of injections did not influence the progression

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure 1: Eye numbers group-wise

Figure 1: Eye numbers group-wise

 

Figure 2: Smoking affect on VA Progression

Figure 2: Smoking affect on VA Progression

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×